Table 3.
The Inconsistency of Loop-Specific Approach for Efficacy and Safety
| Loop | IF | seIF | z_value | p_value | CI_95 | |
|---|---|---|---|---|---|---|
| Δ Weight(kg) | A-C-E | 1.897 | 1.857 | 1.022 | 0.307 | (0.00,5.54) |
| A-B-C | 0.443 | 1.037 | 0.427 | 0.670 | (0.00,2.48) | |
| Δ HbA1c (%) | A-C-D | 0.360 | 0.181 | 1.987 | 0.047 | (0.00,0.72) |
| Total adverse events | A-D-E | 0.352 | 0.317 | 1.109 | 0.267 | (0.00,0.97) |
| A-C-E | 0.217 | 0.534 | 0.406 | 0.684 | (0.00,1.26) | |
| A-B-C | 0.129 | 1.108 | 0.116 | 0.908 | (0.00,2.30) | |
| Serious adverse events | A-D-E | 0.318 | 0.679 | 0.469 | 0.639 | (0.00,1.65) |
| A-B-C | 0.308 | 0.725 | 0.425 | 0.671 | (0.00,1.73) | |
| A-C-E | 0.235 | 0.510 | 0.460 | 0.645 | (0.00,1.24) | |
| Hypoglycemic events | A-D-E | 0.034 | 0.393 | 0.088 | 0.930 | (0.00,0.81) |
| A-B-C | 0.126 | 0.525 | 0.241 | 0.810 | (0.00,1.15) | |
| A-C-E | 0.051 | 0.376 | 0.136 | 0.892 | (0.00,0.79) |
Notes: A: Placebo; B: Liraglutide 1.8mg; C: Liraglutide 3.0mg; D: Semaglutide 1.0mg; E: Semaglutide 2.4mg.